Quest Diagnostics Stock - Sunday background on diagnostics leader
21.06.2026 - 08:06:41 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 08:05 CET. Details in the imprint.
Quest Diagnostics (US74834L1008) is one of the largest clinical laboratory operators in the United States, with its stock listed on the New York Stock Exchange under the ticker DGX. With no fresh market-moving news from major wire services or investor relations today, the focus shifts to a Sunday background look at the diagnostics specialist and its stock.
Background and data on Quest Diagnostics stock
Key figures, recent earnings reports and regulatory filings give investors a structured view of Quest Diagnostics and its position in the US diagnostics market.
What the filings show
Quest Diagnostics last reported quarterly results in late April, citing stable demand for routine testing and a normalization of COVID-related volumes compared with prior years. According to the company, base business growth has helped offset the decline in pandemic-related testing revenue.
In its most recent Form 10-Q filed with the US Securities and Exchange Commission, Quest Diagnostics outlined revenue, margin trends and capital allocation priorities, including ongoing share repurchases and dividends. The filing also detailed reimbursement dynamics and regulatory risks that continue to shape the diagnostics landscape.
Background focus on management and governance
Quest Diagnostics is led by Chair, President and CEO Jim Davis, who took over the top role from longtime CEO Steve Rusckowski. Management emphasizes disciplined capital allocation, focusing on organic investments, tuck-in acquisitions and consistent shareholder returns through dividends and buybacks.
The board of directors includes a mix of healthcare, technology and finance experts, providing oversight on strategy, risk and compliance. Governance documents and committee charters published on the company website outline structures for audit, quality and compliance oversight within the laboratory network.
How the company makes money
Quest Diagnostics generates most of its revenue from diagnostic information services, including routine blood tests, advanced diagnostics and esoteric testing performed in its laboratories for physicians, hospitals, employers and insurers. The company operates a broad network of laboratories and patient service centers across the United States.
Where the stock trades today
Quest Diagnostics stock (US74834L1008) last closed on the New York Stock Exchange at $194.79 on 06/18/2026, with an after-hours indication of $195.02 in extended trading that evening.
Key facts on Quest Diagnostics stock
- Company: Quest Diagnostics Inc.
- ISIN: US74834L1008
- WKN: 929716
- Ticker: DGX
- Venue: NYSE
- Price (as of 06/18/2026, 19:45 ET): 194.79 USD (close), 195.02 USD (after hours)
- Market cap: 21,500,000,000 USD (approx., as of 06/18/2026)
- Sector / Industry: Health Care / Health Care Services - Diagnostic Services
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
